重组抗 EGFR×抗 CD3 双特异性抗体武装的活化 T 细胞对实体瘤具有广泛反应性和增强效力 Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours. PubMed 2022/12/01 发表Ann MedQ1 · IF 4.9(JCR 2025) 靶点:EGFR技术:双特异性抗体胰腺癌前列腺癌胶质母细胞瘤地区:美国